Berberine functions as an allosteric activator of AMP-activated protein kinase (AMPK), increasing its phosphorylation and downstream signaling through the glucose metabolic pathway. This mechanism modulates metabolic aging by enhancing insulin sensitivity, improving mitochondrial function, and reducing cellular senescence through SIRT1/NAD+-dependent pathways. In preclinical models, AMPK activation extends lifespan and delays age-related metabolic dysfunction; human evidence demonstrates improvements in glucose homeostasis, lipid profiles, and inflammatory markers associated with cardiometabolic healthspan, though direct lifespan data in humans remain absent. The clinical relevance for longevity practice centers on berberine's capacity to address metabolic dysfunction as a root cause of age-related disease rather than treating individual pathologies.
Berberine is sold as a dietary supplement and is not FDA-approved as a drug for any indication. It has been studied for glucose-related effects comparable in some respects to metformin.
Berberine is often discussed as a metformin comparator for AMPK-related metabolic effects, but its human longevity-specific trial base is considerably less developed than metformin's.
Published human evidence specific to longevity outcomes has not yet met Geroevidence's minimum threshold for a formal evidence tier.
Berberine has gastrointestinal side effects reported in some studies and known interaction potential with other glucose-lowering agents; longevity-specific safety data remains limited.
Berberine is sometimes discussed as a metformin alternative due to overlapping AMPK-related mechanisms, but it lacks metformin's extensive human RCT and longevity-relevant outcome data. See the metformin profile for comparison.